 | Welcome to Signals!
Signals is the online magazine of biotechnology analysis for the biotechnology industry. We provide analysis of trends of interest to biotechnology, medical device and pharmaceutical companies involved in the pursuit of important medical products.
Scroll through this document for an explanation of the site - its navigation, purpose and contributors.
To contact Signals, call 925-952-3870, or e-mail at signals_edit@recap.com
Navigating Signals
Front Page (left)  | About Signals A site map and guide to Signals. Note: On all but the home page, this symbol returns the reader to the Signals home page
Help navigating the Signals site
Find Signals articles mentioning a specific company, person, or term.
Contents The open book allows you to browse through Signals articles by category |
| Feature screens Here we flag timely developments of interest. Topics may relate to changes in strategy (Turn Signals); alarming or problematic news (Mayday); commentary by the Signals staff on issues or upcoming features (Signals v. Noise); stories about technology transfer and issues related to academic science and licensing (School Zone); and every Wednesday, a trivia contest (Game Day) |
| News Links: Signals is not a news service, but we provide links to other sites for breaking news and press releases. |
| Link to ReCap, publisher of Signals. |
Front Page (center)
| Cover story In-depth articles examining alliance, financing, strategic, technology and other trends of interest to biotechnology players. Typically, a cover story will be featured prominently here for a couple of weeks. |  | | Recent articles A list the three most recent feature articles. At the bottom of this list is a link to the table of contents. |
top
Signals' Mission
Signals is an online magazine of analysis for biotechnology executives. Our mission is to provide comprehensive, timely analysis of major trends and new developments critical to the pursuit of novel new medical therapies and diagnostic products utilizing advanced technology. Our main areas of emphasis are alliances, financial trends, technology developments, and profiles of interesting people and companies.
top
Signals' Staff & Contributors
Signals is proud to feature the work of experienced science and business journalists.
Staff
Editor
Jennifer Van Brunt, Ph.D. joined Signals as its new editor in April 1999, bringing with her 15 years of experience covering the biotechnology industry as a journalist and reporter. Before joining Signals, Jennifer was the editor of BioWorld Financial Watch, a weekly fax publication that covers trends in the biotech industry. She also held a position as senior editor at BioWorld Today. Prior to joining the BioWorld group, Jennifer was the managing editor at Bio/Technology (now known as Nature Biotechnology). Concurrently, she was an associate professor in the adjunct faculty of the department of biochemistry and molecular biology at the University of Miami School of Medicine. She received her Ph.D. degree in genetics from the University of California at Davis and went on to hold positions as a postdoctoral fellow and a research associate at the National Jewish Center for Immunology and Respiratory Medicine in Denver.
E-mail: jennifervb@recap.com
Current Contributors
Ken Garber is a Michigan-based science writer. A former staff writer for the Ann Arbor Observer, he now writes for Science, Technology Review, Nature Biotechnology, Nature Medicine and the Journal of the National Cancer Institute.
E-mail: KENGARBER@prodigy.net
Bruce Goldman is a San Francisco-based freelance writer who has been covering health and biotechnology since 1983, when, as a graduate student studying cell biology at Harvard University, he wrote several articles for the Harvard Medical School Health Letter. His work has appeared in Health, Hippocrates, Genetic Engineering News, Parenting, Stanford Medicine, the Miami Herald, San Francisco Chronicle and Examiner, San Jose Mercury News, and other publications. Bruce has held top editorial slots at MoreLife, a preventive-health magazine; the Stanford University-based Portable Stanford Book Series; and Bechtel Briefs, an award-winning corporate magazine of Bechtel Group, Inc. He is also former associate editor of Stanford Magazine and co-author of two books on technological, demographic, environmental, economic, and social trends -- Fast Forward: Where Technology, Demographics, and History Will Take America and the World in the Next Thirty Years (Harper Business, 1994) and 2020 Visions: Long View of a Changing World (Portable Stanford Book Series, 1991).
E-mail: brucegoldman@earthlink.net
Tom Hollon, Ph.D., is a science writer and editor based in Rockville, MD. He was the founding editor of Modern Drug Discovery and conducted research at the National Institutes of Health, the Pasteur Institute and the University of Washington. His articles have appeared in The Scientist, Nature Medicine, Nature Biotechnology and The Lancet. He has a Ph.D. in microbiology from the University of Washington and the Hutchinson Cancer Center.
Email: thollon@starpower.net
Lisa Piercey has worked in or written about the biotechnology industry since 1988. She was the Business Editor and founder of BioWorld Financial Watch and the Washington Editor of BioWorld Today. Her articles have appeared in BioWorld Today, BioWorld Financial Watch, BioPeople, Pharmaceutical Outcomes News, Outcomes Measurement & Management and the BBI Newsletter. Prior to joining BioWorld, Lisa was employed at XOMA Corp. where she worked on the FDA advisory committee presentations for two experimental agents. She has a masters degree in international affairs from Columbia University. While in graduate school, Lisa worked at Newsweek International.
E-mail: lnatanson@recap.com
........................................................................................
Prior Contributors
Bryce G. Hoffman is an award-winning business and technology journalist covering the biotechnology and information technology industries. Formerly the editor of ReCap IT Magazine, Hoffman has also written for newspapers across Northern California. He began his career in journalism at The Nation magazine in 1992, after majoring in anthropology and philosophy at San Francisco State University. In 1999, Hoffman completed a fellowship in economics at the California State University, Hayward. He has been honored by the California Newspaper Publishers Association for his investigative reporting on technology-related issues.
E-mail: bghoffman@attbi.com
Therese Bogan provided graphic and lay-out support for Signals. Therese has five years experience in recording, theater and multimedia production. Currently, she is involved in publishing Fnord, a literary periodical, and contributes to Fabula Magazine. Therese has a Humanities degree in Cultural Theory from the University of Minnesota, Twin Cities.
Renee Deger Former West Coast correspondent for Venture Capital Journal, Renee began covering venture capital industry and the financing of biotechnology and technology companies in 1993. Her work has appeared online at ZDNet and in The Milwaukee Journal, The Milwaukee Sentinel and the The Kansas City Star.
Naomi Freundlich was formerly Science Editor at Business Week, where she authored and edited many stories involving biotechnology, medicine, the environment and other science-related subjects. Prior to Business Week, she was an editor at Popular Science, and at Industrial Chemical News. She has an M.A. in Science and Environmental Reporting from New York University, and a B.A. from Middlebury College. Her work has also appeared in the Harvard Health Letter, McCall's, New Scientist, the New York Daily News and other publications.
Joan O'C. Hamilton Former Bureau Chief for Business Week magazine's San Francisco bureau, Joan has covered the biotechnology and health care industry since 1983. In addition to scores of feature articles, her cover stories on the field have included in-depth articles on Genentech, AIDS, Cancer research, the 1992 biotech IPO phenomenon and other science and business developments. Joan was a founding editor of BioWorld in 1989. Joan edited Signals from July 1997-December 1998. Joan is still a contributor to Business Week and to Business Week online, as well as to The Stanford Magazine, The San Jose Mercury, and other publications. Her work has also appeared in BioPeople, Stanford Medicine, California Lawyer, The New York Times, The San Francisco Examiner and The Boston Globe. She has degrees in communication and political science from Stanford University.
Mary Beth Regan is a former Congressional correspondent for Business Week. Mary Beth covered national politics, science and environmental issues in the magazine's Washington office. Prior to joining Business Week, Mary Beth covered science and environmental issues for two Tribune Co. newspapers. In 1992, she received the nation's top environmental reporting award for coverage of ground water contamination in Florida. She graduated from Columbia University's School of Journalism in 1988 and wrote about regional business for the Washington Post from 1985 to 1987. Today, she contributes to Business Week, Business Week Online, the Washington Post and other publications.
Julie Tilsner Formerly an assistant editor at Business Week Magazine in New York City, Julie helped design and launch the UpFront Section of BW in 1994. She has more than 10 years experience as a writer, editor and researcher. Her work has appeared in the Los Angeles Times, the New York Times, Lingua Franca, Parenting Magazine and Women's Wire (online), among other publications. She is also the author of a humor book on turning 30. Julie has an undergraduate degree in art history from San Jose State University and an M.S. from Columbia University's Graduate School of Journalism.
Margaret Young is a freelance writer and editor who first began covering biotechnology in 1988, when she originated the biotechnology coverage for the Alameda Newspaper Group. While there, she won a first-place award for best business coverage from the California Newspaper Publisher's Association. She has since written for a variety of business and legal publications as well as edited reports on the pharmaceutical industry for the market research firm of Frost & Sullivan. She has a master's in print journalism from Stanford University and an undergraduate degree from Sarah Lawrence College.
top
Recombinant Capital
Signals is published by Recombinant Capital (Recap), a San Francisco Bay-based consulting firm specializing in biotechnology alliances and capitalization.
Recap's mission is to ensure availability of adequate resources for deserving biotechnology enterprises by providing comprehensive and timely advice and analysis related to the environment for corporate and product development and alliance formation. Signals is one vehicle for doing that, because it is our belief that high quality analysis and access to information makes the process more efficient.
Recap was founded in 1988 by Mark Edwards. Prior to founding Recap, Mr. Edwards was manager of business development at Chiron. Mr. Edwards has a bachelor's degree in economics and an MBA, both from Stanford University. Recap's clients include more than 150 biotechnology and pharmaceutical companies, plus several universities, investment banking and venture firms active in the biotechnology area.Recap's consulting activities are completely separate from the work of Signals.
For more information, follow this link. Or call Recap at 925-952-3870.
Mark Edwards
Publisher, Signals
top |